<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">705</article-id><article-id pub-id-type="doi">10.36691/RJA705</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">BRONCHIAL ASTHMA. WHAT IS IT POSSIBLE TO DO FOR ACHIEVEMENT OF CONTROL OF THIS DISEASE?</article-title><trans-title-group xml:lang="ru"><trans-title>БРОНХИАЛЬНАЯ АСТМА. ЧТО МОЖНО СДЕЛАТЬ ДЛЯ ДОСТИЖЕНИЯ КОНТРОЛЯ ЗАБОЛЕВАНИЯ?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kurbacheva</surname><given-names>O M</given-names></name><name xml:lang="ru"><surname>Курбачева</surname><given-names>О М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Immunology</institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2012</year></pub-date><volume>9</volume><issue>2</issue><issue-title xml:lang="en">NO2 (2012)</issue-title><issue-title xml:lang="ru">№2 (2012)</issue-title><fpage>28</fpage><lpage>34</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Фармарус Принт Медиа</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2014-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/705">https://rusalljournal.ru/raj/article/view/705</self-uri><abstract xml:lang="en"><p>Bronchial asthma is the disease extended around the world, having optimized medical approaches to which maintaining, it is possible to reduce it’s influence on the patient and society. Approaches applied now to a cumulative assessment of asthma burden are unreliable: doctors underestimate real weight of a disease at the patients receiving antiasthmatic therapy, and patients overestimate extent of control of the disease. However, control of bronchial asthma can be reached with treatment according to the modern recommendations. Article is devoted to some aspects of the combined anti-inflammatory therapy of bronchial asthma by various pharmacological means and their combinations.</p></abstract><trans-abstract xml:lang="ru"><p>Бронхиальная астма является распространенным во всем мире заболеванием, оптимизировав лечебные подходы к ведению которого можно снизить влияние его на больного и общество. Применяемые в настоящее время подходы к совокупной оценке тяжести астмы являются ненадежными: врачи недооценивают реальную тяжесть заболевания у больных, получающих противоастматическую терапию, а пациенты переоценивают степень контроля своего заболевания. Однако контроль бронхиальной астмы может быть достигнут на фоне лечения в соответствии с современными рекомендациями, предполагающими применение противовоспалительных средств в сочетании с бронхолитической терапией или без нее. Статья посвящена некоторым аспектам комбинированной противовоспалительной терапии бронхиальной астмы различными фармакологическими средствами и их комбинациями.</p></trans-abstract><kwd-group xml:lang="en"><kwd>bronchial asthma</kwd><kwd>principles of the therapy</kwd><kwd>disease control</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>бронхиальная астма</kwd><kwd>принципы терапии</kwd><kwd>контроль заболевания</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Busse W.W., Lemanske R.F. Jr. N. Engl. J. Med. 2001, v. 344, p. 350-362.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Luskin A.T J. Allergy Clin. Immunol. 2005, v. 115, S539-S545.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>GINA. Global Strategy for Asthma Management and Prévention 2007. http://ginasthma.org.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>NAEPP, NHLBI, NIH. NIH publication 07-4051. Published August 2007. http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bousquet J. et al. Allergy. 2007, v. 62, p. 102-112.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kwok M.Y et al. Pediatr. 2006, v. 117, p. 71-77.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Partridge M.R. et al. BMC Pulm. Med. 2006, v. 6, p. 13.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>LaForest L. et al. Int. Arch. Allergy Immunol. 2005, v. 136, p. 281-286.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Valovirta E. et al. BMC Pulm. Med. 2006, v. 6 (suppl 1), p. 3.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>The Workshop Expert Panel. Management of Allergic Rhinitis and its Impact on Asthma (ARIA) Pocket Guide. A Pocket Guide for Physicians and Nurses, 2001.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kay A.B. Allergy and allergic diseases. First of two parts. N Engl. J. Med. 2001, v. 344, p. 30-37.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Varner A.E., Lemanske R.F. Jr. The early and late asthmatic response to allergen. In: Busse WW Holgate ST eds. Asthma and Rhinitis. 2nd ed. Oxford, UK: Blackwell Science. 2000, p. 1172-1185.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Togias A. Unique mechanistic features of allergic rhinitis. J. Allergy Clin. Immunol. 2000.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Louis R., Lau L.C.K., Bron A.O. et al. The relationship between airways inflammation and asthma severity. Am. J. Respir. Crit. Care Med. 2000, v. 161, p. 9-16.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>McLeish A.C. et al. J. Asthma. 2010, v. 47, p. 345-361.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Thomson N.C. et al. Eur. Respir J. 2004, v. 24, p. 822-833.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jang A.S. et al. J. Korean Med. Sci. 2009, v. 24, p. 209-214.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Price D., Thomas M. BMC Pulm. Med. 2006, v. 6 (suppl 1), p. 6.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zwarenstein M. et al. BMJ. 2008, v. 337, p. 2390.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Virchow J.C. et al. Add-on montelukast in inadequately controlled asthma patients in а б-month open-label study: The MONtelukast In Chronic Asthma (МОХ1СА) study. Respir Med. 2010, v. 104, p. 644-651.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Virchow J.C. et al. А suberoup analysis of the MONICA study: А 12-month open-label study of add-on montelukast treatment in asthma patients. Published online ahead of print</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>September 2010. J. Asthma 2010. doi:10.3109/02770903. 2010.494753.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Masoli M. et al. Allergy. 2004, v. 59 (5), p. 469-478.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>World Health Organization/European Environment and Health Information System. Fact Sheet No. 3.1. May 2007. euro.who.int/document/ehi/enhis factsheet 3 1.pdf. Accessed</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>23 August 2010.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Cazzoletti L. et al. J Allergy Clinlmmunol. 2007, v. 120 (6), p. 1360-1367.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Summit for Change in Asthma Management. The Brussels Declaration. 1st ed. May 2007. summitforchange.eu/pdf/The Brussels Declaration 1st Edition 10th May.pdf. Accessed 23 August 2010.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Holgate S. et al. Eur. Respir. J. 2008, v. 32, p. 1433-1442.</mixed-citation></ref></ref-list></back></article>
